ArticlePLoS medicine2018
Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: A cohort study.
Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Are socio-economic inequalities related to cardiovascular disease risk? A systematic review and meta-analysis of prospective studies.BMC cardiovascular disorders · 2024Pooled it
- Serum/plasma biomarkers and the progression of cardiometabolic multimorbidity: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- Inequalities in the progress of multiple chronic conditions: A systematic review of longitudinal studies.PloS one · 2022Pooled it
- Paradoxical Obesity and Overweight Disparities Among Sexual Minority Men: A Meta-Analysis.American journal of men's healthPooled it
- A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data.The lancet. Healthy longevity · 2022Trial
- Association of anxiety, depressive symptoms, and inflammatory indices with cardiometabolic multimorbidity.Brain, behavior, & immunity - health · 2026Article
- A Cross-Nationally Validated Nomogram for Cardiometabolic Multimorbidity in Overweight/Obese Older Adults: CHARLS and HRS Cohorts.Diabetes, obesity & metabolism · 2026Article
- Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Estimated Cardiorespiratory Fitness and Incident Cardiometabolic Multimorbidity in Older Adults: A Prospective Cohort Study.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Age at Menopause and Trajectories of Multimorbidity Progression to Mortality: A Multi-State Analysis of UK Biobank Data.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Integrating social and cardiometabolic risk factors in predicting cardiometabolic multimorbidity: a Bayesian model development and internal validation in Swedish middle-aged adults.Scientific reports · 2026Article
- The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Article
- Life-course patterning of MLTC clusters and their patient-centred burden in depression: a population-based study using real-world data.BMJ mental health · 2026Article
- Association of plant-based diet with cardiometabolic multimorbidity trajectory: A prospective study in UK Biobank.The journal of nutrition, health & aging · 2026Article
- Article
- Association of accelerated phenotypic aging, lifestyle and genetic risk with progression of cardiometabolic multimorbidity: a multi-state model analysis.GeroScience · 2026Article
- Risk factors for multimorbidity of cardiovascular diseases in the prospective Million Women Study.Open heart · 2026Article
- Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China.Cardiovascular diabetology · 2026Article
- Relationship between socioeconomic inequality and multimorbidity progression in UK Biobank data.Communications medicine · 2026Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMultimorbidity is increasingly common and is associated with adverse health outcomes, highlighting the need to broaden the single-disease framework that dominates medical research. We examined the role of midlife clinical characteristics, socioeconomic position, and behavioural factors in the development of cardiometabolic multimorbidity (at least 2 of diabetes, coronary heart disease, and stroke), along with how these factors modify risk of mortality. METHODS AND
findingsData on 8,270 men and women were drawn from the Whitehall II cohort study, with mean follow-up of 23.7 years (1985 to 2017). Three sets of risk factors were assessed at age 50 years, each on a 5-point scale: clinical profile (hypertension, hypercholesterolemia, overweight/obesity, family history of cardiometabolic disease), occupational position, and behavioural factors (smoking, alcohol consumption, diet, physical activity). The outcomes examined were cardiometabolic disease (diabetes, coronary heart disease, stroke), cardiometabolic multimorbidity, and mortality. We used multi-state models to examine the role of risk factors in 5 components of the cardiometabolic disease trajectory: from healthy state to first cardiometabolic disease, from first cardiometabolic disease to cardiometabolic multimorbidity, from healthy state to death, from first cardiometabolic disease to death, and from cardiometabolic multimorbidity to death. A total of 2,501 participants developed 1 of the 3 cardiometabolic diseases, 511 developed cardiometabolic multimorbidity, and 1,406 died. When behavioural and clinical risk factors were considered individually, only smoking was associated with all five transitions. In a model containing all 3 risk factor scales, midlife clinical profile was the strongest predictor of first cardiometabolic disease (hazard ratio for the least versus most favourable profile: 3.74; 95% CI: 3.14-4.45) among disease-free participants. Among participants with 1 cardiometabolic disease, adverse midlife socioeconomic (1.54; 95% CI: 1.10-2.15) and behavioural factors (2.00; 95% CI: 1.40-2.85), but not clinical characteristics, were associated with progression to cardiometabolic multimorbidity. Only midlife behavioural factors predicted mortality among participants with cardiometabolic disease (2.12; 95% CI: 1.41-3.18) or cardiometabolic multimorbidity (3.47; 95% CI: 1.81-6.66). A limitation is that the study was not large enough to estimate transitions between each disease and subsequent outcomes and between all possible pairs of diseases.
conclusionsThe importance of specific midlife factors in disease progression, from disease-free state to single disease, multimorbidity, and death, varies depending on the disease stage. While clinical risk factors at age 50 determine the risk of incident cardiometabolic disease in a disease-free population, midlife socioeconomic and behavioural factors are stronger predictors of progression to multimorbidity and mortality in people with cardiometabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.